BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19192983)

  • 1. Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.
    Chandwani S; Wentworth C; Burke TA; Patterson TF
    Curr Med Res Opin; 2009 Feb; 25(2):385-93. PubMed ID: 19192983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echinocandin antifungals: review and update.
    Morrison VA
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):325-42. PubMed ID: 16597212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.
    Vekeman F; Weiss L; Aram J; Ionescu-Ittu R; Moosavi S; Xiao Y; Cheng WY; Bhak RH; Tawadrous M; Capparella MR; Montravers P; Duh MS
    BMC Infect Dis; 2018 Aug; 18(1):438. PubMed ID: 30157797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical claims and current applications of the potent echinocandin antifungals.
    Smith L; Lu SE
    Recent Pat Antiinfect Drug Discov; 2010 Jan; 5(1):58-63. PubMed ID: 19929842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical review of echinocandins in pediatric patients.
    VandenBussche HL; Van Loo DA
    Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
    Kofla G; Ruhnke M
    Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echinocandins in the management of invasive fungal infections, Part 2.
    Morris MI; Villmann M
    Am J Health Syst Pharm; 2006 Oct; 63(19):1813-20. PubMed ID: 16990627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
    Liu X; Liu D; Pan Y; Li Y
    J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of micafungin in the antifungal armamentarium.
    Ikeda F; Tanaka S; Ohki H; Matsumoto S; Maki K; Katashima M; Barrett D; Aoki Y
    Curr Med Chem; 2007; 14(11):1263-75. PubMed ID: 17504145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic changes in surgical intensive care unit patients undergoing echinocandin treatment.
    Koch C; Schneck E; Arens C; Markmann M; Sander M; Henrich M; Weigand MA; Lichtenstern C
    Int J Clin Pharm; 2020 Feb; 42(1):72-79. PubMed ID: 31748967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.